Seeking Alpha

BioDelivery +8.6% AH; FDA approves Bunavail

  • The FDA has approved BioDelivery's (BDSI) Bunavail for the "maintenance treatment of opioid dependence." The drug is expected to launch late in Q3.
  • BioDelivery estimates peak U.S. sales potential of up to $250M. A deal has been reached with Ashfield Market Access to "provide managed markets and trade support" for Bunavail.
From other sites
Comments (1)
  • airborne44
    , contributor
    Comment (1) | Send Message
    Anything since July 7th with their meeting with the FDA???
    Something has to happen???
    4 Aug 2014, 02:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs